ADVFN Logo

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.

NIPT Premaitha

9.10
0.00 (0.00%)
Last Updated: 00:00:00
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Premaitha LSE:NIPT London Ordinary Share GB00BN31ZD89 ORD 0.1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 9.10 9.00 9.20 0.00 00:00:00
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
0 0 N/A 0

Premaitha Health PLC Directorate change (7612C)

03/10/2018 7:00am

UK Regulatory


Premaitha (LSE:NIPT)
Historical Stock Chart


From Mar 2019 to Mar 2024

Click Here for more Premaitha Charts.

TIDMNIPT

RNS Number : 7612C

Premaitha Health PLC

03 October 2018

Premaitha Health PLC

("Premaitha" or the "Company")

Directorate change

Premaitha Health PLC (AIM: NIPT), a leading international molecular diagnostics group focused on non-invasive prenatal testing ("NIPT"), announces that, further to the announcement made by the Company on 20 September 2018, Mr Hayden Jeffreys has been appointed as Group Commercial Director to the Company following completion of customary director due diligence. Mr Jeffreys will take up his position on the Board of Premaitha with immediate effect.

Pursuant to Rule 17 and Schedule 2(g) of the AIM Rules for Companies, the following information is disclosed in respect of Mr Hayden William Jeffreys (aged 42):

 
 Current Appointments   Appointments in the last 
                         5 years 
 Cambridge DX Limited   Delta Biologicals Srl 
                        Diamedix Inc 
                        Drew Scientific Inc 
                        Erba Diagnostics Inc 
                        Erba Diagnostics Mexico S.A. 
                        Erba Mannheim Gmbh 
                        Immunovision Inc 
                        Jas Diagnostics Inc 
                        Lumora Limited 
 

There is no further information regarding Mr Jeffreys required to be disclosed under the AIM Rules.

This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.

Enquiries

 
 Premaitha Health plc                              Tel: +44 (0) 161 
                                                    667 6865 
 Lyn Rees, Chief Executive Officer 
 Barry Hextall, Chief Financial Officer 
  Joanne Cross, Head of Marketing 
 investors@premaitha.com 
 
 Cairn Financial Advisers LLP (Nomad)              Tel: +44 (0) 20 
                                                    7213 0880 
 Liam Murray / James Caithie 
 
 finnCap (Broker)                                  Tel: +44 (0) 20 
                                                    7220 0500 
 Geoff Nash / Matthew Radley (Corporate Finance) 
 Tim Redfern (Corporate Broking) 
 
 Vigo Communications                               Tel: +44 (0) 20 
                                                    7390 0234 
 Ben Simons / Fiona Henson / Antonia Pollock 
 premaitha@vigocomms.com 
 

About Premaitha

Premaitha is an international molecular diagnostics group which uses the latest advances in DNA analysis technology to develop safer, faster and regulatory approved genetic screening tests. The Group's primary focus is on non-invasive prenatal tests (NIPT) for pregnant women - an emerging, multi-billion dollar global market.

Premaitha's IONA(R) test was launched in 2015 as the first CE-IVD NIPT test in Europe. It enables laboratories and healthcare practitioners to offer a complete CE-marked NIPT system in-house. The IONA(R) test is performed on a maternal blood sample - which contains traces of placental DNA - and estimates the risk of a fetus being affected with Down's syndrome or other genetic conditions.

Unlike existing prenatal screening methods, due to its high level of accuracy, the IONA(R) test can significantly reduce the number of women subjected to unnecessary invasive follow up diagnostic procedures, such as amniocentesis, which are costly, resource intensive and carry a risk of miscarriage.

In March 2017, Premaitha acquired Yourgene Bioscience, a specialist next generation sequencing and bioinformatics company based in Taiwan, with its own NIPT screening test that operates on the same Thermo Fisher next-generation sequencing platform as Premaitha's IONA(R) test. Yourgene brings significant benefits to the Group through expanded market access in Asia - the world's fastest growing NIPT market - as well as opportunities for cross-selling and the ability to jointly develop expanded test content both within NIPT and beyond.

Premaitha is headquartered in Manchester, England, with Yourgene offices in Taipei and Singapore. Its shares trade on the AIM market of the London Stock Exchange (AIM: NIPT). For further information, please visit www.premaitha.com. Follow us on twitter @PremaithaHealth.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

BOAUGGAAUUPRGQP

(END) Dow Jones Newswires

October 03, 2018 02:00 ET (06:00 GMT)

1 Year Premaitha Chart

1 Year Premaitha Chart

1 Month Premaitha Chart

1 Month Premaitha Chart

Your Recent History

Delayed Upgrade Clock